RIPK4 and ovarian cancer: By contrast, RIPK4 overexpression predicts poor prognosis in patients with ovarian cancer, cervical SCC, pancreatic cancer, bladder cancer, and osteosarcoma (Qi et al., 2018; Liu et al., 2015; Liu et al., 2018; Yi et al., 2020; Liu et al., 2021).